Literature DB >> 17488857

Age-related macular degeneration and recent developments: new hope for old eyes?

Brid Morris1, Fraser Imrie, Ana-Maria Armbrecht, Baljean Dhillon.   

Abstract

Age-related macular degeneration (AMD) is the commonest cause of blindness in the population over 60 years of age and accounts for over 50% of those registered blind in the UK. The incidence is increasing and as older generations live longer a growing number of patients will be affected in the future. Affected patients lose central vision, important in all aspects of everyday life. This review outlines risk factors for AMD, clinical features, treatment and management strategies for patients, families and physicians caring for those with AMD. Recent trials are included along with practical clinical advice. While there is no curative treatment at present, intervention can reduce the risk of developing AMD and limit disease progression if it occurs. These modalities are discussed here. As new discoveries in the field of genetics and novel therapies emerge, a brighter future seems certain for the ageing population.

Entities:  

Mesh:

Year:  2007        PMID: 17488857      PMCID: PMC2600068          DOI: 10.1136/pgmj.2006.052944

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  49 in total

1.  Macular translocation with 360-degree peripheral retinectomy impact of technique and surgical experience on visual outcomes.

Authors:  C A Toth; S F Freedman
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Intravitreal avastin: the low cost alternative to lucentis?

Authors:  Philip J Rosenfeld
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

3.  Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.

Authors:  Ziad F Bashshur; Ali Bazarbachi; Alexandre Schakal; Zeina A Haddad; Christelle P El Haibi; Baha' N Noureddin
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

4.  Risk of incident age-related eye diseases in people with an affected sibling : The Beaver Dam Eye Study.

Authors:  B E Klein; R Klein; K E Lee; E L Moore; L Danforth
Journal:  Am J Epidemiol       Date:  2001-08-01       Impact factor: 4.897

5.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

8.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

9.  Age-specific causes of bilateral visual impairment.

Authors:  L M Weih; M R VanNewkirk; C A McCarty; H R Taylor
Journal:  Arch Ophthalmol       Date:  2000-02

10.  Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial).

Authors:  Stuart Richer; William Stiles; Laisvyde Statkute; Jose Pulido; James Frankowski; David Rudy; Kevin Pei; Michael Tsipursky; Jill Nyland
Journal:  Optometry       Date:  2004-04
View more
  12 in total

1.  Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice.

Authors:  Shigeru Honda; Takayuki Nagai; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-02       Impact factor: 3.117

2.  Metamorphopsia and letter recognition.

Authors:  Emily Wiecek; Steven C Dakin; Peter Bex
Journal:  J Vis       Date:  2014-12-01       Impact factor: 2.240

3.  Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye.

Authors:  Shigeru Honda; Takayuki Nagai; Naoshi Kondo; Masahide Fukuda; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  J Ophthalmol       Date:  2010-07-25       Impact factor: 1.909

Review 4.  Stem cells as tools in regenerative therapy for retinal degeneration.

Authors:  Volker Enzmann; Esma Yolcu; Henry J Kaplan; Suzanne T Ildstad
Journal:  Arch Ophthalmol       Date:  2009-04

5.  Prevalence and risk factors of early-stage age-related macular degeneration in patients examined at a health promotion center in Korea.

Authors:  Byung Gil Moon; Soo Geun Joe; Jong-uk Hwang; Hong Kyu Kim; Jaewon Choe; Young Hee Yoon
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

Review 6.  Impact of Climate Change on Eye Diseases and Associated Economical Costs.

Authors:  Lucía Echevarría-Lucas; José Mᵃ Senciales-González; María Eloísa Medialdea-Hurtado; Jesús Rodrigo-Comino
Journal:  Int J Environ Res Public Health       Date:  2021-07-05       Impact factor: 3.390

7.  Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration.

Authors:  Peter K Kaiser
Journal:  Core Evid       Date:  2008-07-31

8.  Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Wataru Matsumiya; Shigeru Honda; Hiroaki Bessho; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  J Ophthalmol       Date:  2011-06-12       Impact factor: 1.909

9.  Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size.

Authors:  Yoshihiro Nishimura; Maiko Taguchi; Takafumi Nagai; Masashi Fujihara; Shigeru Honda; Mamoru Uenishi
Journal:  Clin Ophthalmol       Date:  2012-03-06

10.  Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.

Authors:  Wataru Matsumiya; Shigeru Honda; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  BMC Ophthalmol       Date:  2013-04-04       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.